Literature DB >> 21215707

Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

Imanol Arozarena1, Berta Sanchez-Laorden, Leisl Packer, Cristina Hidalgo-Carcedo, Robert Hayward, Amaya Viros, Erik Sahai, Richard Marais.   

Abstract

We show that in melanoma cells oncogenic BRAF, acting through MEK and the transcription factor BRN2, downregulates the cGMP-specific phosphodiesterase PDE5A. Although PDE5A downregulation causes a small decrease in proliferation, its major impact is to stimulate a dramatic increase in melanoma cell invasion. This is because PDE5A downregulation leads to an increase in cGMP, which induces an increase in cytosolic Ca(2+), stimulating increased contractility and inducing invasion. PDE5A downregulation also this leads to an increase in short-term and long-term colonization of the lungs by melanoma cells. We do not observe this pathway in NRAS mutant melanoma or BRAF mutant colorectal cells. Thus, we show that in melanoma cells oncogenic BRAF induces invasion through downregulation of PDE5A. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215707     DOI: 10.1016/j.ccr.2010.10.029

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  95 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

Review 3.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

Review 5.  A brief history of melanoma: from mummies to mutations.

Authors:  Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

6.  The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.

Authors:  Manali S Phadke; Patrizia Sini; Keiran S M Smalley
Journal:  Mol Cancer Ther       Date:  2015-04-14       Impact factor: 6.261

7.  RhoJ modulates melanoma invasion by altering actin cytoskeletal dynamics.

Authors:  Hsiang Ho; Amelia Soto Hopkin; Rubina Kapadia; Priya Vasudeva; Jonathan Schilling; Anand K Ganesan
Journal:  Pigment Cell Melanoma Res       Date:  2013-01-07       Impact factor: 4.693

8.  TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells.

Authors:  Michele B Weiss; Ethan V Abel; Melanie M Mayberry; Kevin J Basile; Adam C Berger; Andrew E Aplin
Journal:  Cancer Res       Date:  2012-12-07       Impact factor: 12.701

9.  In silico studies of the interaction between BRN2 protein and MORE DNA.

Authors:  Ivan Evangelista do Vale Coelho; Denise Costa Arruda; Alex Gutterres Taranto
Journal:  J Mol Model       Date:  2016-08-27       Impact factor: 1.810

Review 10.  Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Authors:  Geoffrey T Gibney; Jane L Messina; Inna V Fedorenko; Vernon K Sondak; Keiran S M Smalley
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.